Bellicum Is Outperforming and So Should Be Its Stock

Bellicum Pharmaceuticals (BLCM) announced results from the BP-004 multicenter clinical trial for children with Primary Immune Deficiencies (PIDs) and hemoglobinopathies. The candidates received an add-back of Bellicum’s BPX-501 modified T cells following a haploidentical, T cell-depleted hematopoietic stem cell transplant (haplo-HSCT).

The data were presented in oral and poster sessions today during the 58th Annual Meeting of the American Society of Hematology (ASH).

Results: All 35 treated children are alive and cured of their underlying disease. No graft vs. host . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.